Pharmacovigilance in older adults – New podcast episode

In focus / 29 October 2024

Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?


Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfizer discusses what makes this patient group so vulnerable to adverse drug reactions, how poor representation and using age alone to define older adults exacerbates this problem, and suggests ways forward in monitoring drug safety in older patients.

Related Articles

From Nobel prize to PV: How neural networks inspired vigiGroup

Ecopharmacovigilance: Ensuring environmental safety from pharmaceuticals

Guarding nature: The role of ecopharmacovigilance in preventing pharmaceutical pollution

You may also like

From Nobel prize to PV: How neural networks inspired vigiGroup

Machine learning has long been used at UMC. In fact, our vigiGroup method stems from neural networks pioneered by one of this year’s Nobel laureates in Physics.

In focus / 05 December 2024

Guarding nature: The role of ecopharmacovigilance in preventing pharmaceutical pollution

EcoPV aims to monitor and manage the environmental impact of pharmaceuticals. How may we best support this effort?

In focus / 01 September 2024

Ecopharmacovigilance: Ensuring environmental safety from pharmaceuticals

Pharmacovigilance monitors the safety of the medicines we use, but what about those that get into our environment?

In focus / 15 October 2024